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BACKGROUND: The goals of treating patients with cancer are to cure the disease, prolong survival, and improve quality of life. Immune cells 
in the tumor microenvironment have an important role 
in regulating tumor progression. Therefore, stimulating 
immune reactions to tumors can be an attractive therapeutic 
and prevention strategy.
CONTENT: During immune surveillance, the host provides 
defense against foreign antigens. By targeting surface 
antigens expressed on tumor cells, monoclonal antibodies 
have demonstrated efficacy as cancer therapeutics. Recent 
successful antibody-based strategies have focused on 
enhancing antitumor immune responses by targeting 
immune cells, irrespective of tumor antigens. The use of 
antibodies to block pathways inhibiting the endogenous 
immune response to cancer, known as checkpoint blockade 
therapy, has stirred up a great deal of excitement among 
scientists, physicians, and patients alike. Clinical trials 
evaluating the safety and efficacy of antibodies that block 
the T cell inhibitory molecules cytotoxic T-lymphocyte-
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associated protein 4 (CTLA-4) and programmed cell death 1 
(PD-1) have reported success in treating subsets of patients. 
Adoptive cell transfer (ACT) is a highly personalized 
cancer therapy that involve administration to the cancer-
bearing host of immune cells with direct anticancer activity. 
In addition, the ability to genetically engineer lymphocytes 
to express conventional T cell receptors or chimeric antigen 
receptors has further extended the successful application of 
ACT for cancer treatment. 
SUMMARY: The underlying basis of cancer immunotherapy 
is to activate a patient’s own T cells so that they can kill 
their tumors. Reports of amazing recoveries abound, where 
patients remain cancer-free many years after receiving 
the therapy. The idea of harnessing immune cells to fight 
cancer is not new, but only recently have scientists amassed 
enough clinical data to demonstrate what a game-changer 
cancer immunotherapy can be. This field is no stranger to 
obstacles, so the future looks very promising indeed.
KEYWORDS: immune checkpoint, adoptive cell transfer, 
neoantigen, monoclonal antibody
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Introduction
The past few decades have seen a grounds well of research 
on the immune system yielding a deeper understanding 
of how cancer progresses and offering new ways to stop 
it.(1) In 1891, William Coley injected cancer patients 
with bacteria to ignite an immune response, a strategy is 
experiencing a revival. Now immunologists are finding 
ways to harness the immune system, including training 
immune cells to recognize a patient’s particular cancer.(2,3) 
The finding that tumors can actively suppress immunity has 
led to the development of checkpoint blockades that prevent 
this suppression.(4)
 Last year’s Lasker DeBakey Clinical Research Award 
was awarded to James Allison for discovering that antibody 
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blockade of the T cell molecule cytotoxic T-lymphocyte-
associated protein 4 (CTLA-4) unleashes the body’s 
immune response against malignant tumors. This lead to 
development of multiple immune checkpoint therapies that 
are prolonging and saving the lives of many cancer patients.
(5) The successful treatment of multiple mouse tumors 
with anti-CTLA-4 impressed many immunologists, but the 
perceived failure of many earlier immune-based therapies 
created a very high bar for advancing immune checkpoint 
therapy to the clinic. The turning point came with 3 trial 
comparing Ipilimumab to a melanoma peptide vaccine in 
metastatic melanoma patients who had the human leukocyte 
antigens (HLA) A0201 allele.(6) Key to the success of the 
study was the decision to evaluate overall survival rather 
than response rate, and in the large study, Ipilimumab 
monotherapy resulted in more than 20% long-term 
survival. The success of this trial led the Food and Drug 
Administration (FDA) to finally approve Ipilimumab for the 
treatment of metastatic melanoma in 2011.
 At around the time when Ipilimumab was being 
considered for FDA approval, renewed excitement about 
immune checkpoint therapy came from clinical studies 
targeting a second immune inhibitory molecule, programmed 
cell death 1 (PD-1). PD-1 was discovered by Tasuku Honjo 
in 1992 in a screen for genes expressed during programmed 
cell death of a T cell hybridoma.(7) Unlike CTLA-4, which 
functions mainly during primary immune responses, PD-1 
signaling results in exhaustion of activated T cells, an 
anergic-like state that is thought to be due to a shift in the 
utilization of metabolic substrates.(8) Antibody blockade 
of PD-1 was shown to enhance anti-tumor and anti-viral 
responses in animal models, suggesting that this could be 
another immune checkpoint target for cancer.
 Schering Plough acquired an anti-PD1 antibody 
developed by Organon, and this was introduced into the 
clinic as Pembrolizumab, after the company was acquired by 
Merck, and was approved by the FDA for treating advanced 
melanoma in 2014. The Bristol-Myers Squibb (BMS) drug, 
Nivolumab, was approved very shortly thereafter. The 
change in attitude of clinical oncologists and immunologists 
toward the place of immune modulation in combating 
cancer guarantees that there will be many exciting advances 
in immune-based therapies in the years ahead.(5)Cancer Immunology
evolution of tumor cells resulting from the progressive 
accumulation of multiple genetic (11) or epigenetic changes 
(12). Alterations in tumor stroma microenvironments may 
also promotes the development of tumor cell heterogeneity 
through extrinsic activation of certain tumor cell signaling 
pathways.(13) Moreover, recent studies have suggested that 
heterogeneity is a result of the hierarchical organization of 
tumor cells by a subset of cells with stem or progenitor cell 
features known as cancer stem cells (CSC).(14)
 The concept of cancer as an abnormal stem cell disease 
was proposed based on the similar abilities of cancer cells 
and normal stem cells to self-renew, produce heterogeneous 
progeny and also divide in an unlimited fashion.(15,16) 
However, the CSC hypothesis has only recently been 
experimentally validated by the identification of a subset of 
certain self-renewing stem cell marker-positive cells with a 
hierarchical organization.(17,18) The self-renewal capacity 
is confirmed by serial in vitro clonogenic growth and in vivo 
tumorigenicity. CSC are also known as tumor-initiating cells 
or tumor-propagating cells. CSC are highly tumorigenic, 
metastatic, chemotherapy and radiation resistant, 
responsible for tumor relapse after therapy, and able to 
divide symmetrically and asymmetrically to orchestrate the 
tumor mass.(19) Therefore, CSC are a pivotal target for the 
eradication of many cancers including liver cancer.(20)
 Some cancer cells may be disseminated and leave 
tumor relentlessly, only to perish en masse, find a good time 
to reinitiate a full-fledged tumor and settle there arising 
metastasis in distant tissues.(21,22) Yet when metastasis 
occurs, it creates complications that account for the vast 
majority of deaths from cancer. Cancer cells that succeed 
in doing this task possess not only the attributes of tumor-
initiating cells, but also the ability to exert this capacity 
under harshly adverse conditions. Metastasis therefore is 
driven by CSC at their best, or at their worst, depending on 
your perspective.(23)
 As tumors are heterogeneous and show distinctive 
genetic and epigenetic profiles, there may not be a single 
biomarker that will prove sufficient information for 
predicting treatment response and patient outcome. Examples 
of informative tumor biomarkers are molecular features of 
neoplastic cells, including epidermal growth factor receptor 
(EGFR) mutations in lung cancer (24,25); microsatellite 
instability (MSI) in colorectal cancer (26-28); estrogen 
receptor 1 (ESR1), progesterone receptor (PGR) and erb-b2 
receptor tyrosine kinase 2 (ERBB2/HER2) expression in 
breast cancer (29,30); transmembrane protease, serine 2 and 
ETS-related gene fusion (TMPRSS2-ERG) translocation 
in prostate cancer (31); and CpG island methylation, and 
Although originally considered as monoclonal, tumor cells 
show heterogeneous morphology and behavior.(9,10) This 
heterogeneity has traditionally been explained by the clonal 
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kirsten rat sarcoma viral oncogene (KRAS), B-raf proto-
oncogene (BRAF), phosphatidylinositol-4,5-bisphosphate 
3-kinase, catalytic subunit alpha (PIK3CA) and tumor 
protein(TP)-53 mutations in multiple cancer types (32-34). 
In addition to tumor markers, host factors which include 
the immune response to the tumor might determine tumor 
behavior or serve as informative biomarkers.(35)
 During carcinogenesis, tumor cells interact with 
a complex microenvironment which is composed of 
extracellular matrix and non-neoplastic host cells, 
including mesenchymal cells, vascular endothelial cells and 
inflammatory or immune cells. Inflammatory and immune 
cells are present to varying degrees (from absent to intense) 
in the tumor microenvironment, which can be observed 
routinely in pathology practice. The tumor microenvironment 
provides nutrients, oxygen, growth factors, cytokines, and 
other chemical mediators that support tumor proliferation, 
survival, invasion, and metastasis for the cancer cells.(36) 
The immune system can respond to cancer cells in two 
ways, which are by reacting against tumor-specific antigens 
(molecules that are unique to cancer cells) or by reacting 
against tumor-associated antigens (molecules that are 
expressed differently by cancer cells and normal cells).(37) 
Immunity to carcinogen-induced tumors in mice is directed 
against the products of unique mutations of normal cellular 
genes. These mutant proteins are tumor-specific antigens.
(38)
 The immunosurveillance hypothesis posits that the 
immune system recognizes malignant cells as foreign 
agents and eliminates them. This idea was contentious 
until the understanding of tumor immunity improved and 
better techniques and animal models became available to 
test it rigorously. Mouse models in which immune effector 
mechanisms such as the type 1 interferon (IFN) were 
eliminated by gene deletion showed a clear reduction in the 
incidence of tumors by the immune system.(39-43) In animal 
models, the encounter between the immune system and a 
nascent tumor initiates a process termed ‘immunoediting’ 
that can bring about three outcomes, those are elimination 
of the cancer; cancer equilibrium, in which there is immune 
selection of less immunogenic tumors during an antitumor 
immune response; and tumor escape, the growth of tumor 
variants that resist immune destruction.(44,45)  
 Relation between immune system and cancer 
is complex and dynamic. Whereas there are a series 
of scenarios in which the immune system exerts an 
antineoplastic surveillance, there are also other situations in 
which immune processes contribute to the transformation 
and progression of malignant tumors.(46) This paradigm 
of tumor immunology is known as cancer immunoediting, 
and is composed of three stages, which are elimination, 
equilibrium and escape (Figure 1).(46-48) The elimination 
phase is difficult to study, and clear evidence of its existence 
is scarce in humans, as elimination is believed to take 
place in a preclinical stage and often times represents 
the resolution of the disease process. Elimination was 
thought to be carried by the innate and adaptive immune 
systems, and natural killer (NK),  natural killer T (NKT), 
cluster of differentiation (CD)8+ cytotoxic and CD4+ 
lymphocytes, macrophages as well as dendritic cells (DC) 
that participating in the presentation, recognition and lysis 
of cells displaying tumor antigens.(49) Elimination is often 
limited, and some tumor cells are left alive, either due to 
their antigenic or immune-related gene expression profile 
allows these cells to survive the initial immune surveillance 
entering an equilibrium phase. In this phase, there is a 
dynamic balance between anti-tumoral immunity and tumor 
cells.
 Cancer development was showed in patients 
transplanted with donor-derived tumors, even when there 
was no cancer clinical manifestation found. This suggest 
the existence of human equilibrium stage.(49,50) The 
equilibrium is thought to be maintained by adaptive immunity.
(46) At last, escape is the stage in which those tumor cells 
that are not detectable or have developed mechanisms to 
avoid immune recognition and lysis, get selected and then 
grow into a symptomatic lesion. An illustrating example 
of this phenomenon is the use of a vaccine targeting the 
EGFR variant III (EGFRvIII) in glioblastoma. Clinical 
studies have shown some effectiveness in patients with 
glioblastoma that originally expressed EGFRvIII, while 
upon recurrence expression was lost in the tumors.(51) In 
addition to the induction of an immunosuppressive state, 
another paradigm in tumor-immunology is the tendency for 
tumors to minimize the display of their antigens, which is 
resulting in another mechanism for evasion of anti-tumor 
immunity. The relative lack of a tumor-specific antigenic 
repertoire and the impairment of antigenic presentation by 
major histocompatibility complex (MHC) class I by tumors 
can diminish tumor recognition by cytotoxic T-lymphocytes.
(52)
 Tumors can suppress immunity both systemically 
and in the microenvironment of the tumor.(53) In 
addition to producing immunosuppressive molecules 
such as transforming growth factor β (TGF-β) (54) and 
soluble Fas ligand (55), many human tumors produce the 
immunosuppressive enzyme indoleamine-2,3-dioxygenase 
(IDO) (56,57). This enzyme was previously known for its 
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Figure 1.  Cancer immunoedit-ing 
paradigm.(46) IDO: indoleamine-
2,3-dioxygenase, TGF-β: transforming 
growth factor β, IL: interleukin, TNF: 
tumor necrosis factor,  NKG2D: natural-
killer group 2 member D, TRAIL: TNF-
related apoptosis inducing ligand, MØ: 
macrophage. (Adapted with permission 
from Springer).
role in maternal tolerance to antigens from the fetus (58) 
and, more recently, as a regulator of autoimmunity that 
mediates inhibition of T-cell activation (59). Stereoisomers 
of 1-methyl-tryptophan inhibit IDO (60), and when 
administered to tumor-bearing mice, they restore immunity 
and thereby allow immune rejection of the tumor (61). Such 
stereoisomers might have a role in the treatment of patients 
with cancer.(62)
 Tumor microenvironment can be dominated by 
regulatory T cells that suppress antitumor effector T cells 
by producing the immunosuppressive cytokines TGF-β 
and interleukin (IL)-10.(35) High numbers of these cells 
can be detected in non-small-cell lung cancer and ovarian 
cancer.(63) Murine tumors that produce TGF-β can convert 
antitumor effector T cells into regulatory T cells, thereby 
escaping their own destruction by immune cells.(64,65) 
The immunosuppressive effects of a tumor can also be 
systemic. An increase in regulatory T cells has been found 
in the peripheral blood of patients with head and neck 
cancer (66,67) or melanoma (68).  Patients with colorectal 
cancer or pancreatic tumors have increased numbers of 
activated granulocytes (69) and myeloid-derived suppressor 
cells (70), both of which suppress tumor-specific T cells in 
mice (71,72). Up to now, the field of tumor immunology 
is providing an initial understanding of how these tumors 
might be avoiding immune recognition.(46)
Cancer Immunotherapy
For more than half a century, scientists have been trying 
to turn the body’s immune system against cancer. But 
decades of failures have revealed that tumors have the 
ability to evade, tamp down and overwhelm the normal 
immune response. Most modern immune therapies try to 
get the immune system to recognize and attack tumor cells.
(4) The administration of monoclonal antibodies (mAb)
against tumor antigens in HER2-positive breast cancer 
(Trastuzumab) (73), B-cell lymphomas (Rituximab) (74), 
and head and neck, lung, and colorectal cancers that express 
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the EGFR (Cetuximab) (75-77) is clinically effective (Table 
1).(62) Efforts are ongoing to produce antibodies with new 
effector functions against known targets or to identify new 
targets for therapeutic antibodies. These targets could be 
tumor antigens or molecules produced by tumors to promote 
their own survival, such as vascular endothelial growth 
factor (VEGF) (78) and TGF-β (64). Antibodies can also 
target immune cells at the tumor site to aid the activation 
of effector cells and promote more effective antitumor 
immunity.(79)
 Targeting host immunity is an attractive strategy for 
cancer therapy and prevention because therapy resistance 
is less likely to develop when host cells are targeted 
instead of altered molecules within tumor cells.(37,38) 
The latter approach frequently results in resistance to the 
initial targeted therapy owing to, for example, an acquired 
mutation in a domain of the therapeutic target that interacts 
with the drug. Host immunity can be targeted by the use 
of activated autologous peripheral-blood mononuclear 
cells (sipuleucel-T) (80,81), or the use of specific 
immunoregulatory molecules, such as recombinant vaccinia 
vector (targeting prostate-specific antigen) (82). One such 
treatment, the vaccine sipuleucel-T (marketed as Provenge 
by Dendreon Corporation in Seattle), was approved by the 
US FDA in 2010 for use in prostate cancer, which is a move 
that generated a lot of excitement. But the drug has proven 
disappointing, with benefits limited to a small percentage 
of patients, Dendreon is now reported to be for sale. The 
problem, researchers have slowly been realizing, is that 
stepping on the immune system’s gas pedal isn’t enough. 
It is also necessary to release its brakes, and that is where 
immune checkpoint blockades come in.(4)
 In 2011, the US FDA approved the anti-CTLA4 drug 
Ipilimumab (developed by BMS and marketed as Yervoy), 
which was based on Allison’s research and eventually 
saved the lives of some of Ribas’s patients. CTLA-4 is 
not the only checkpoint being targeted by researchers and 
drug developers. Early trials suggest that drugs that block a 
different checkpoint, which is PD-1, are even more effective 
and have fewer side effects than Ipilimumab.(83) In recent 
studies, checkpoint blockades produced improvements 
in between 20% and 65% of patients, depending on the 
Table 1. Immunologic reagents approved by FDA for cancer therapy.(62) (Adapted with permission from 
Massachusets Medical Society).
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drug, dosage and type of cancer. In one long-term study 
of Ipilimumab in patients with advanced melanoma, 22% 
of the 1,861 patients survived for three years, and 17% for 
seven years or longer (with median survival nearly a year).
(84) Historically, average survival was six to nine months.
(84) Early research suggests that Ipilimumab may be even 
more effective when combined with other drugs. In further 
evidence for the value of drug combinations, Ipilimumab 
and Nivolumab appear to complement each other.(4) 
A few years ago, when Michel Sadelain spoke about 
adoptive cell transfer (ACT) therapy at cancer meetings, 
his colleagues were dubious about what seemed a drastic 
and unconventional approach: harvesting and genetically 
altering his patient’s immune cells to train them to attack 
her cancer.(3)
 There are three strategies for ACT therapies, the most 
developed of which is the simplest. The tissue surrounding 
a tumor is likely to contain immune cells with antitumor 
activity, so doctors take a sample of this tissue and select 
those T cells that have been primed to attack the cancer. They 
culture these cells in the lab until they have enough, and re-
infuse the cells back to patients along with the T-cell growth 
factor IL-2, which promotes the proliferation of antigen-
specific T cells.(3) This approach, called tumor-infiltrating 
lymphocyte (TIL) therapy, has been used successfully to 
treat only one type of cancer, that is metastatic melanoma. 
T cells that have been primed to attack a specific cancer 
are difficult to collect in a blood sample, but in melanoma 
these lymphocytes enter the tumor and are easy to biopsy. 
Currently, the success of TIL in melanoma is not transferable 
to other cancers, because it is harder to collect tumor-
specific T cells. For those cancers, researchers are working 
hard in order to genetically modify T cells to hone their 
cancer killing skills.(3)
 To do this, researchers are taking a couple of 
approaches. One option, called T cell receptor (TCR) 
therapy, involves giving the cells new receptors that allow 
them to recognize specific cancer antigens; the receptors 
can even be modified to improve their ability to find and 
bind to their targets. A more flexible tactic, called chimeric 
antigen receptor (CAR) therapy, avoids this constraint. It 
uses a gene that encodes artificial, antibody-like proteins 
that bind the antigens studding the tumor cell’s surface 
without needing to match the patient’s immune type. So part 
of the optimization process includes giving both TCR- and 
CAR-based T-cell therapies the optimal mix of enhancing 
molecules and targets to achieve the best response.
 As ACT therapies move closer to the mainstream, 
the next big step will be investigating whether and how to 
integrate them with other cancer immunotherapies. Despite 
lingering questions, scientists and clinicians are enthusiastic 
about the potential of ACT. It represents a flexible platform 
for cancer treatment that can be tweaked and adapted as 
further discoveries are made. 
 Immunity results from a complex interplay between 
the adaptive immune system (which is antigen-specific) 
and the innate immune system (which is not). B cells and 
T cells of the adaptive immune system use receptors that 
recognize antigens, or their derived peptides, in a highly 
specific manner. DC provide an essential link between the 
innate and adaptive immune responses. The generation of 
anticancer immunity depends on DC presenting cancer 
antigens to T cells. But cancers can create an environment 
that inhibits T cells. The aim of DC vaccination is to boost 
cancer-specific effector T cells that can not only fight 
existing cancer but also induce immunological memory to 
control the recurrence of cancer.(2)
 Topalian notes that patients treated with immune 
therapies could potentially gain a lifetime of protection, 
similar to the buffer against certain diseases offered by 
childhood vaccines. “We hope that the same thing is 
happening in cancer,” she says. “We hope that we are re-
educating the immune system and that, even if it doesn’t 
completely destroy every last cancer cell, it can keep it in 
check for a very long time.”(85) It is tempting to ask whether 
immunotherapy is evolving to become standard care for 
cancer patients, beyond those with advanced disease.  Is there 
a place for therapeutic regimens that combine checkpoint 
blockade with other strategies? While we are nowhere near 
having all the answers, these studies provide a wealth of 
data supporting the idea that somatic mutations in cancer 
cells are an important target of endogenous anti-tumor 
responses. Checkpoint blockade is effective at rescuing the 
anti-tumor effect and it is plausible that understanding the 
dynamics of the response to this therapy will also help the 
development of alternative and personalized approaches to 
treat cancer.(86)
mAb Targetting Cancer-associated Proteins
Immune system is regulated by a reptilian complex balance 
of signals transmitted by stimulatory and inhibitory 
receptors. More than any other discovery, mAb have enabled 
us to identify and manipulate these molecules, provide an 
important new class of immunostimulatory therapeutics that 
can complement small-molecule therapeutics under active 
development.(87,88) Specific recognition by mAb has 
permitted the identification of cytokines and cell-surface 
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the antimitotic drug monomethyl auristatin E. It has recently 
approved as a treatment of anaplastic large cell lymphoma 
(NCT00866047) and Hodgkin lymphoma (NCT00848926).
 Nine mAbs targeting six cancer-associated proteins 
(HER2/neu, EGFR, VEGF, CD20, CD52 and CD33) are 
approved for the treatment of solid and hematotogical 
malignancies. In addition to antagonizing oncogenic 
pathways, these biotherapeutics may act by opsonizing 
tumor cells and triggering their death or removal by 
ADCC or phagocytosis.(93) Ongoing investigations in 
murine models and patients increase the possibility that 
they may also stimulate adaptive immune responses in 
some settings.(94) Recently, the successful conjugation 
of toxins to antibodies has been achieved, and these have 
induced a clinical response in patients who are refractory 
to the naked antibody.(95) The concurrent administration of 
immunostimulatory cytokines such as IL-2 and granulocyte-
macrophage colony-stimulating factor may also enhance the 
efficacy of antibody therapy.(96)
The myriad of genetic and epigenetic alterations which 
are characteristic of all cancers provide a diverse set of 
antigens that the immune system can use to distinguish 
tumor cells from their normal counterparts. In the case of 
T cells, the ultimate amplitude and quality of the response, 
which is initiated through antigen recognition by the TCR, 
is regulated by a balance between co-stimulatory and 
inhibitory signals, that is immune checkpoints.(97,98) Under 
normal physiological conditions, immune checkpoints are 
crucial for the maintenance of self-tolerance (the prevention 
of autoimmunity) and also to protect tissues from damage 
when the immune system is responding to pathogenic 
infection. The expression of immune-checkpoint proteins 
can be dysregulated by tumor as an important immune 
resistance mechanism.
 A novel strategy of immunotherapy called checkpoint 
inhibition is hovered to dramatically revamp the treatment 
of a broad spectrum of malignancies. Checkpoint inhibitors 
function by modulating the immune systems’ endogenous 
mechanisms of T cell regulation Ipilimumab (YervoyTM, 
BMS, New York, NY) has become standard treatment 
for metastatic melanoma.(6,99) Ipilimumab binds and 
blocks inhibitor signaling mediated by the T cell surface 
coinhibitory molecule cytotoxic T lymphocyte antigen 4 
(CTLA-4). Because the mechanism of action is not specific 
to one tumor type, and because a wealth of preclinical 
data support the role of tumor immune surveillance acros 
multiple malignancies (100,101), Ipilimumab I being 
molecules involved in humoral antibody-mediated and 
cellular immune responses.(79)
 Antibodies may target tumor cells by engaging surface 
antigen differentially expressed in cancers. For example, 
Rituximab target CD20 in non-Hodgkin B cell lymphoma, 
Trastuzumab targets HER2 in breast cancer, and Cetuximab 
targets EGFR in colorectal cancer. Blocking the ligand-
receptor growth can evoke the tumor cell death and survival 
pathways. Innate immune effector mechanisms engaging 
the Fc portion of antibodies via Fc receptors including 
complement-mediated cytotoxicity (CMC) and antibody-
dependent cellular cytotoxicity (ADCC) are emerging as 
equally important.(89,90)
 The natural properties of antibodies which enable 
specific antigen engagement can be leveraged and 
improved upon by engineering approaches that increase 
antitumor activity. One example is the creation of bispecific 
antibodies (bsAb) with dual affinities for a tumor antigen 
and either another tumor antigen or a target in the tumor 
microenvironment. As the Fc domain of mAbs does not 
directly activate T cells, CD3, the activating receptor for T 
cells, is a common target of bsAb. Catumaxomab is a bsAb 
that binds the tumor antigen epithelial cell adhesion molecule 
(EpCAM), CD3, and innate effector cells through an intact 
Fc portion.(91) This bsAb, termed a Triomab, effectively 
kills tumor cells in vitro and in vivo and induces protective 
immunity, most likely through the induction of memory T 
cells. Catumaxomab’s success in a phase II/III clinical trial 
led to its approval by the European Commission in 2009 for 
the treatment of malignant ascites. This success spurred the 
development of other Triomabs targeted against the tumor 
antigens HER2/neu (Ertumaxomab), CD20 (Bi20/FBTA05; 
NCT01138579), GD2 and GD3 (Ektomun).(90)
 Some efforts that made earlier to enhance the 
antitumor effects of mAbs focused on boosting their 
direct cytotoxic effects on the targeted cells. Conjugation 
of radionuclides (radioimmunotherapies (RIT)), drugs 
(antibody-drug conjugates (ADC)), toxins (immunotoxins), 
and enzymes (antibody-directed enzyme prodrug therapy 
(ADEPT)) yielded a multitude of antibodies, or antibody-
like molecules, with varying clinical efficacy. Three 
conjugated antibodies have translated into FDA-approved 
therapies for hematological malignancies. Two are RIT 
agents targeting CD20 and are indicated for treatment 
of relapsed and/or Rituximab-refractory follicular or 
low-grade lymphomas: 90Y-ibritumomab tiuxetan and 
131I-tositumomab. At the minimum of a dozen other 
RIT agents are in active development, including ten that 
target solid tumors.(92) Brentuxima vedotin, the third 
approvedimmunoconjugate, is a CD30 targets ADC, carries 
Immune Checkpoint Therapy
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investigated as a treatment for patient with prostate, lung, 
renal, and breast cancer among other tumor types.(102) The 
field of immune checkpoint therapy has joined the ranks 
of surgery, radiation, chemotherapy, and targeted therapy 
as a pillar of cancer therapy. Therefore, in contrast to most 
currently approved antibodies for cancer therapy, antibodies 
that block immune checkpoints do not target tumor cells 
directly, instead they target lymphocyte receptors or their 
ligands in order to enhance endogenous anti tumor activity.
(103)
 Three new immune checkpoint agents now have been 
approved by the US FDA for the treatment of melanoma, 
arising new hopes more approved agents for treating lung 
cancer, kidney cancer, bladder cancer, prostate cancer, 
lymphoma, and many other tumor types. Ipilimumab an 
antibody against CTLA-4 was approved in 2011, and two 
antibodies against PD-1 (Pembrolizumab and Nivolumab) 
were approved in 2014.
 Another category of immune-inhibitory molecules 
includes certain metabolic enzymes, such as IDO, which 
is expressed by both tumor cells and infiltrating myeloid 
cells, and arginase, which is produced by myeloid-derived 
suppressor cells.(60,104-109) These enzymes inhibit 
immune responses through local depletion of amino acids 
that are essential for anabolic functions in lymphocytes 
(particularly T cells) or through the synthesis of specific 
natural ligands for cytosolic receptors that can alter 
lymphocyte functions. These enzymes can be inhibited to 
enhance intratumoral inflammation by molecular analogues 
of their substrates which act as competitive inhibitors or 
suicide substrates.(110-112) These drugs represent a radical 
and disruptive change in cancer therapy in two ways. First, 
they target molecules involved in T cell regulation as 
the soldiers of the immune system, rather than the tumor 
cell. Second, perhaps in a more radical shift, the therapy 
is not designated to activate the immune system to attack 
particular targets on tumor cells, but to remove inhibitory 
pathways that block effective antitumor T cell responses.
 Understanding of immune checkpoint therapy has 
led to new weapons against cancer which is elicit durable 
clinical responses and showed long-term remission for 
patiets, and provide an important advance in clinical 
advances about regulatory pathways in T cells and enhancing 
antitumor immune responses. Tumor cells express tumor-
specific antigens in the form of complexes of tumor-derived 
peptides bound to MHC molecules on the cell, this will be 
the target of T cells in this therapy. Tumor antigens can be 
derived from oncogenic viruses, differentiation antigens, 
epigenetically regulated molecules such as cancer testis 
antigens, or neoantigens derived from mutations associated 
with the process of carcinogenesis.(113)
 Recognition of antigen-MHC complexes by the T cell 
antigen receptor is not sufficient for activation of naïve T 
cells, but additional co-stimulatory signals  are required 
that are provided by the engagement of CD28 on the T cell 
surface with B7 molecules (CD80 and CD86) on the antigen-
presenting cell (APC).(97,115) Expression of B7 molecules 
is limited to subsets of hematopoietic cells, especially DC, 
which have specialized the processes for efficient antigen 
presentation.(114)
 Further insights into the fundamental mechanisms 
which regulate early aspects of T cell activation may 
provide one from many possible explanations for the 
limited effectiveness of these early vaccine trials. By the 
mid-1990s, it became clear that T cell activation was even 
more complex, and in addition to initiating proliferation 
and functional differentiation T cell activation also induced 
an inhibitor pathway that could eventually attenuate an 
terminate T cell responses. Expression of CTLA-4 a gene 
with very high homology to CD28, is initiate by T cell 
activation, and, like CD28, CTLA-4 binds B7 molecules, 
albeit with much higher affinity. Although CTLA-4 was first 
thought to be another co-stimulatory molecule (116), two 
laboratories independently showed that it oppose CD28 co-
stimulation and down-regulated T cell responses (117,118). 
Thus, activation of T cells result in induction of expression 
of CTLA-4, which accumulates in the T cell at the T cell-
APC interface reaching a level where it eventually block 
co-stimulation and abrogates an activated T cell response 
(Figure 2).(114)
 The preclinical successes of anti-CTLA-4 I achieving 
tumor rejection in animal models and the ultimate clinical 
success which opened a new field of immune checkpoint 
therapy.(103,119) It is now known that there are many 
additional immune checkpoints. PD-1 was shown in 2000 to 
be another immune checkpoint that limits the responses of 
activated cells.(120) PD-1, like CTLA-4, has two ligands, 
PD-L1 and PD-L2, which are expressed on man cell types. 
The function of PD-1 is completely distinct from CTLA-
4 in that PD-1 does not interfere with co-stimulation, but 
interferes with signaling mediated by the T cell antigen 
receptor.(97) Also, one of its ligands, PD-L1 (B7-H1), can 
be expressed on many cell types, including T cells, epithelial 
cells, endothelial cells, and tumor cells after exposure to the 
cytokine IFN-γ, produced by activated T cells.(121) This 
leads to the notion that rather than functioning early in T 
cell activation,  PD-1/PD-L1 pathway acts to protect cells 
from T cell attack.
 9
Cancer Immunotherapy (Meiliana A, et al.)Indones  Biomed J.  2016; 8(1): 1-20DOI: 10.18585/inabj.v8i1.189
Figure 2. Blockade of immune checkpoints to enhance T cell responses. After T cell activation, T cells express immune checkpoints 
such as CTLA-4 and PD-1.(114) (Adapted with permission from American Association for the Advancement of Science).
 Two anti-PD-L1 inhibitory antibodies, MPDL3280A 
(Genentech, South San Francisco, CA) and BMS-
936559 (BMS, New York, NY), have undergone clinical 
investigation. Like Nivolumab an MK-3475, these 
antibodies are thought to function principally by blocking 
PD-1/PD-L signaling. Unlike PD-1 antibodies, PD-L 
antibodies spare potential interactions between PD-L2 
and PD-1, but additionally block interaction between PD-
L1 and CD80.(122) In addition to CTLA-4 and PD-1/
PD-L1, plenty other immunomodulatory targets have 
been identified preclinically, many with corresponding 
therapeutic antibodies that are being investigated in clinical 
trials (Figure 3).(102) Majority of these targets are T cell 
surface receptors, but targets in other immunologic cell 
populations are  currently being investigated. For example, 
NK cells express killer immunoglobulin-like receptors 
(KIR), which bind HLA class I molecules on target cells, 
so that delivering an inhibitory signal preventing NK cell-
mediated cytotoxicity.(123) Anti-KIR antibodies may 
release these inhibitory KIR-mediated signals, thereby 
enabling tumor cytotoxicity and immune clearance.
 Efficacy in checkpoint modulation is associated 
with certain immunologic changes, raising the hope that 
biomarkers for response may be identified. Only a minority 
of patients experience long-term survival with Ipilimumab; 
therefore, considerable efforts are ongoing to discover 
predictors of response.(102) Immune and tumor response 
to therapy has been monitored by utilizing a variety of 
laboratory techniques (Figure 4) (102), and numerous 
correlates of response have been retrospectively identified.
 During the past 2-3 years, outcomes of clinical trials 
with Ipilimumab and the PD-1 or PD-L1 inhibitors, alone 
or in combination, have dominated the news coming out of 
clinical oncology meetings. Combination therapy blocking 
both checkpoint pathways has been particularly effective, 
with response rates in advanced melanoma is over 80%. 
These new issues has embraced the biopharmaceutical 
enthusiastically, acquisitions and licensing deals for 
new approaches are almost every week in the news, and 
investigations about new checkpoint targets, negative 
regulators of both adaptive and innate immune cells, 
combination therapy such as with cytokines, co-stimulatory 
Figure 3. Targets of antibody immune 
modulators.(102) BTLA: B- and 
T-lymphocyte attenuator, LAG3: Lymphocyte-
activation gene 3, ICOS: inducible T-cell 
costimulator, GITR: glucocorticoid-induced 
TNFR family related, TIM-3: mucin-domain 
containing-3. (Adapted with permission from 
Annual Reviews).
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molecules, antigen vaccines, and small-molecule modulators 
of signaling pathways and enzymes are being actively done.
(46) The ability of an activated immune response to generate 
a diverse T cell repertoire that adapts to heterogeneous and 
genetically unstable tumors and persistence of memory T 
cells with specificity for tumor antigens, which provide 
efficient recall responses against recurrent disease, make it 
absolutely essential to expand our efforts to find the rational 
combinations to unleash antitumor immune responses for 
the benefit of cancer patients. If it is properly done, seems 
likely that cures for many types of cancer will soon become 
reality.(114)
Figure 4. Strategies for immune monitoring in patients receiving checkpoint agents. (a) Surgical specimens may be analyzed using 
immunohistochemical or immunofluorescence techniques to evaluate tumor antigen expression, T cell infiltrate, tumor necrosis, or 
expression of surface markers such as PD-L1. (b) Using enzyme-linked immunoabsorbent assays or protein arrays, treatment-related 
production of tumor-specific antibodies can be detected in the serum. (c) Flow cytometric analysis of TILs and peripheral blood mononuclear 
cells (PBMC) can quantitate the effect of therapy on immune subsets such as CD25+ T regs, activated CD8+ T cells, or myeloid-derived 
suppressor cells.  (d) Whole blood can be used to evaluate changes in cell count with therapy or changes in cytokine levels.(102) FoxP3: 
forkhead box P3, Eos: eosinophil, ALC: absolute lymphocyte count. (Adapted with permission from Annual Reviews).
Adoptive Immunotherapy
T cells move through tissues, scanning for MHC-peptide 
complexes that specifically activate their TCR. T cells are 
also capable of sensing a variety of signals that can alert them 
to potentially threatening pathogens and to cancer. Tumor-
specific T cells are probably activated through encounters 
with tumor-associated antigens that are presented by 
specialized APC, including DC. However, activated T cells 
are capable of directly recognizing antigens which were 
presented on the surfaces of tumor cells. Based on intravital 
imaging, there is a growing body of evidence showing that 
the migration of tumor-specific T cells is rapidly arrested 
when they encounter their cognate antigens.(124,125)
 Sufficient number of active in vivo antitumor T 
cells was necessary to mediate cancer regression in many 
forms of cancer immunotherapy. ACT has advantages, 
because for use in ACT, the antitumor lympochyte can 
be readily grown in vitro up to 1011, then selection for the 
high-avidity recognition tumor can be performed before 
applied effectively, and the inhibitory factors exist in 
vivo could be released. Perhaps most importantly, ACT 
enables manipulation of the host before cell transfer to 
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provide a favorable microenvironment that better supports 
antitumor immunity. ACT is a living treatment because the 
administered cells can proliferate in vivo and maintain their 
antitumor effector functions.(126)
 ACT has used either natural host cells that exhibit 
antitumor reactivity or host cells that have been genetically 
engineered with antitumor TCRs or CAR. With the use of 
these approaches, ACT has mediated impressive regressions 
in a variety of cancer histologies, including melanoma, 
cervical cancer, lymphoma, leukemia, bile duct cancer, and 
neuroblastoma.(126)
 TILs are primarily Cytotoxic T Lymphocytes (CTL) 
which recognize proteolytically cleaved intracellular tumor 
antigen fragments which have become associated with 
specific MHC class I antigens on the cell surface.(127) 
Expanded TILs have cytolytic activity against the original 
tumor and in contrast to lymphokine activated killer 
(LAK) cells the killing is MHC class I restricted. They are 
selectively broaden from either tumor or draining lymph 
node cells via IL-2, and then re-stimulated with irradiated 
or killed tumor cells to maintain T cell specificity.(128)
 Three forms of ACT using T cells have been 
practiced. The first one is TIL therapy, using lymphocytes 
expanded from a tumor biopsy sample (129); the second 
one is antigen-specific T cell therapy, using endogenous 
T cells sourced from peripheral blood (130-132); and the 
last one is the more recently, the use of gene modified T 
cells engineered to express the desired TCR or CAR with 
occasional remarkable results (133). Immunotherapy based 
on the adoptive transfer of naturally occurring or gene-
engineered T cells can mediate tumor regression in patients 
with metastatic cancer.(125) 
 The capacity to use ACT was facilitated by the 
description of T cell growth factor IL-2 in 1976, which 
provided a means to grow T lymphocytes ex vivo, often 
without loss of effector functions.(134) The direct 
administration of high doses of IL-2 could inhibit tumor 
growth in mice (135), and studies in 1982 demonstrated 
that the intravenous injection of immune lymphocytes 
expanded in IL-2 could effectively treat bulky subcutaneous 
virus-induced lymphoma cells (FBL3) (136). Moreover, 
administration of IL-2 after cell transfer could enhance 
the therapeutic potential of these adoptively transferred 
lymphocytes.(137)
 From many tumor histologies culture grown, only 
melanoma appeared to reproducibly gave rise to TIL 
cultures for specific antitumor recognition. Studies of 
genetic engineering led to lymphocytes capability to express 
antitumor receptors. Following mouse models (138), it was 
shown for the first time in humans in 2006 that administration 
of normal circulating lymphocytes transduced with a 
retrovirus encoding a TCR that recognized the melanoma 
antigen recognized by T-cells 1 (MART-1) could mediate 
tumor regression (139). Administration of lymphocytes 
genetically engineered to express a CAR against the B cell 
antigen CD19 was shown in 2010 to mediate regression of 
an advanced B cell lymphoma.(140) These findings of the 
use of either naturally occurring or genetically engineered 
antitumor T cells set the stage for extended development of 
ACT for the treatment of human cancer (Figure 5).(126)
 In an attempt to broaden the reach of ACT to other 
cancers, techniques were developed to introduce antitumor 
receptors into normal T cells that could be used for therapy 
(Figure 6).(126) The specificity of T cells can be redirected 
by integrating genes encoding either conventional alpha-
beta TCRs or CARs. CARs were pioneered by Gross and 
colleagues in the late 1980s and can be constructed by 
linking the variable regions of the antibody heavy and light 
chains to intracellular signaling chains such as CD3-zeta 
(141), often including co-stimulatory domains encoding 
CD28 (142) or CD137 to fully activate T cells (143,144). 
CARs can provide non-MHC-restricted recognition of cell 
surface components and can be introduced into T cells with 
high efficiency using viral vectors.
 For more patients-specific product approach, a 
paradigm shift required from conventional medicine such 
as pills, vaccines, small molecule inhibitor molecules, and 
antibodies to autologous engineered cell therapies. Some 
have dismissed adoptive T cell immunotherapy as a fringe or 
boutique therapy that would be impossible to commercialize.
(145). Indeed, several challenges must be overcome before 
this disruptive therapy can become widely applicable and 
widely available. Currently, the barriers that we perceive 
fall into two areas. First, robust and reproducible cell culture 
system. T cell engineering process needs complex logistics, 
and some variables standardization in order to scale this 
out for widespread use include developing a leukapheresis 
network, standardizing and scaling up the manufacturing of 
lentiviral vectors, and developing validated cell-shipping 
and chain-of-custody procedures.(146)
 Second, personalized cell therapies cannot become 
broadly available if the cell culture process requires 
extensive manipulation by highly skilled scientists and 
technicians.(147) Hence, automated culture systems need 
to be developed. Previous case in automotive industry, 
cars were initially manufactured in assembly lines, but 
manually. Today’s automobiles are assembled largely by 
robots and other forms of automation.(148) As engineered 
T cell processing becomes more automated, cell products 
will be produced for greater number of patients more 
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efficiently. Seeing the recent entry of the pharmaceutical 
industry to this field, we are optimistic that the resources 
and expertise of the pharmaceutical industry will create 
the infrastructure required for the widespread availability 
of this disruptive technology. Further clinical development 
of engineered T cell therapies in large numbers of patients 
will be challenging but is justified given the magnitude of 
therapeutic effects recently observed (Figure 7).(149)
 The need to develop highly personalized treatments 
for each patient does not fit into the paradigm of major 
pharmaceutical companies that depend on off-the-shelf 
Figure 5. A blueprint for the treatment of patients with T cells recognizing tumor-specific mutations.(126) (Adapted with permission 
from American Association for the Advancement of Science).
reagents that can be widely distributed. However, curative 
immunotherapies for patients with common epithelial 
cancers will probably dictate the need for more personalized 
approaches.(126) Widespread of ACT can not depend 
only on multiple commercial models, but more to the 
development of centralized facilities for tumor-reactive 
TILs production and genetically modified lymphocytes, that 
later can be delivered to the institution who do the treatment. 
New effective approaches for cancer immunotherapy will 
need to trump the convenience of applicable administration 
in treatment.
Figure 6. Gene-modification of peripheral blood lymphocytes.(126) (Adapted with permission from American Association for the 
Advancement of Science).
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 γδ T cells are a subset of T cells that express alternative, 
clonally distributed TCRs and function as innate effectors 
and therefore are restricted in TCR diversity. Compared to 
αβ T cells, they do not target specific peptide antigens and 
are not constrained by the selectivity and restriction of the 
MHC. Although γδ T cells absolute counts are decreased 
and their proliferative capacity is decreased in the setting of 
glioblastoma, they can be expanded and activated ex vivo 
and have shown the ability to recognize and kill glioma 
cells in vitro while sparing cultured normal astrocytes.
(150) Expanded and activated γδ T cells can mediate killing 
of glioblastoma and reduce tumor progression in mouse 
models.(151)
 Cancer immunotherapy trials with autologous cd 
T cells have been investigated in parallel by Japanese, 
Australian and French groups. The French company, Innate 
Pharma, has conducted a phase I study in 10 patients 
with metastatic renal cell carcinoma to determine the 
maximum-tolerated dose of autologous TCRVγ9Vγ2+ γδ T 
cells and the safety of these cells as a therapeutic product.
(152) In parallel with these studies, Kobayashi’s group at 
Tokyo Women’s Hospital investigated seven patients with 
advanced renal cell carcinoma engrafted with autologous 
γδ T cells.(153) Therefore, the authors concluded that γδ 
cell-based immunotherapy is a clinically beneficial and 
safe therapeutic option for patients with advanced renal 
cell carcinoma, whose rates of circulating γδ cells might 
constitute a favorable prognostic indicator.(154) To be 
successful, cancer immunotherapies involving γδ cells will 
require updated protocols which limit anergy and the use 
of drugs able to overcome immunoescape. Even though the 
former contingency is currently an open issue, the second 
one is already well underway.(155)
Figure 7. Engineered T Cells that 
have retargeted specificity.(149) 
Zap70: Zeta-chain-associated 
protein kinase 70, LAT: linker for 
activation of T cells, scFv: single-
chain variable fragment. (Adapted 
with permission from Elsevier).
Immunotherapies which are boosting the ability of 
endogenous T cells to destroy cancer cells have showed 
therapeutic efficacy in a variety of human malignancies. 
Until now, evidence that the endogenous T cell compartment 
could help control tumor growth was in big part restricted to 
preclinical mouse tumor models and to human melanoma.
(113) With respect to human studies, effects of the T cell 
cytokine IL-2 in a small subset of melanoma patients 
provided early clinical evidence of the potential of 
immunotherapy in the said disease. A randomized clinical 
trial was performed in 2010 showed that Ipilinumab, an 
antibody targets T cell checkpoint protein CTLA-4 could 
improve patient survival, even with metastatic melanoma.
(6) As a direct test of the tumoricidal potential of the 
endogenous T cell compartment, a study by Rosenberg and 
colleagues exhibited that infusion of autologous ex vivo 
expanded TIL can induce objective clinical responses in 
metastatic melanoma (156), and at least part of this clinical 
activity is due to cytotoxic T cells (157). Basically, recent 
studies show that T cell-based immunotherapies are also 
effective in a range of other human malignancies.
 With recent technology, we can check the uplevel of 
neoantigens as a tumor-specific mutation consequences, 
and emerging data suggest that this neoantigen play a role 
in the activity of clinical immunotherapies, thus this load 
may be used as cancer immunotherapy biomarker and an 
incentive development of novel therapeutic approaches can 
be provided.(113) In cancer, so-called neoepitope peptides 
are derived from proteins encoded by mutated genes. Recent 
Neoantigens in Cancer Immunotherapy
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ingredient of successful cancer immunotherapies. In other 
words, the genetic damage that on the one hand leads to 
oncogenic outgrowth can also be targeted by the immune 
system to control malignancies. Based on this finding, it will 
be important to engineer therapeutic interventions by which 
neoantigen-specific T cell reactivity is selectively enhanced. 
As it may be, the boosting of neoantigen-specific T cell 
reactivity which can be achieved with such personalized 
immunotherapies will further increase the spectrum of 
human malignancies that respond to cancer immunotherapy.
(113)
DC are designated as professional APC because of their 
capacity to provide T cells with all the signals required 
for antigen-specific T cell activation.(174) For optimal 
activation, T cells must receive at least three coordinated 
signals.(175,176) The first signal is delivered to the TCR by 
MHC molecules presenting antigen-derived peptides. The 
second signal was provided by the binding of co-stimulatory 
molecules with their respective ligands on T-cells. A crucial 
positive co-stimulatory signal is provided by the interaction 
of the B7 family ligands CD80 and CD86, expressed by the 
DC, with the CD28 receptor expressed on the T cell surface. 
The third signal, that called polarization signal, determines 
the commitment of naive CD4+ T helper (TH0) cells 
towards TH1,TH2 or other fates. In the setting of cancer 
immunotherapy, the induction of a TH1 (cellular) immune 
response is highly desirable as this enables the generation of 
CTL capable of recognizing and destroying tumor cells in 
an antigen-specific fashion.(177)
 As well as inducing antigen-specific CTL, which 
are part of the adaptive immune system, DC also capable 
of activating NK cells, which are prime players in the 
innate immune system.(178) NK cells have both cytotoxic 
and immunoregulatory functions and require priming 
to accomplish their full effector potential. Many of the 
cytokines that play a principal role in stimulating NK cell 
functions can be provided by DC, e.g., IL-12, IL-15, IL-18 
and type I IFN.(179)
 A more detailed understanding of the mechanisms 
leading to strong cellular immunity is necessary to 
enable rational approaches to the vaccine design. Two 
recent conceptual breakthroughs in this regard are our 
understanding that DC play a pivotal role in initiating the 
immune response to foreign antigens and the realization 
advances in next-generation DNA and RNA sequencing 
now enable rapid mapping of all expressed mutated genes 
in an individual tumor, and it is possible to predict epitopes 
that are efficiently presented on the surface of cancer cells. 
Thus, it has been demonstrated that CD8+ T cells in human 
melanomas are able to recognize one or more neoepitopes 
from mutant proteins unique to that specific melanoma. 
However, efficient methods for studying CD4+ T cells that 
recognize neoepitopes arising from somatic mutations in 
cancer have been lacking.(158) By using this approach, the 
authors identified neoepitope-specific CD4+ T cells in two 
out of three melanoma patients.(159) The patients’ T cells 
only recognized neoepitopes from the host’s tumor, and they 
preferentially or exclusively noticed the neoepitope over the 
corresponding native, non-mutated peptide, demonstrating 
the exquisite specificity of the CD4+ T cells.
 CD4+ T cells can antecedent cancer regression 
through direct killing of cancer cells, by altering the 
tumor-promoting function of cells in the surrounding 
tumor microenvironment, and by facilitating the induction, 
function and tumor infiltration of cancer-specific CD8+ T 
cells.(160) These studies show that cancer-specific CD4+ 
T cells can cause human tumor regression, adding to the 
importance of the findings by Linnemann, et al.(159) The 
ability to detect neoepitope specific CD4+ T cells now 
allows validation of the hypothesis which the presence of 
neoepitope-specific CD4+ T cells in human tumors correlates 
with overall clinical outcome.
 The mutation in human tumor was considered to 
be individually different at meaningful frequencies and 
fractions, so the T cell reactivity against putative mutation-
derived neoantigens interrogate technologies have to be 
developed based on individual tumor genome. With the 
development of deep-sequencing technologies, it has 
become doable to identify the mutations present within 
the protein-encoding part of the genome (the exome) of 
an individual tumor with relative ease and thereby predict 
potential neoantigens.(161)
 Subsequent studies have demonstrated that cancer 
exome-based analyses can also be exploited in a clinical 
setting, to dissect T cell reactivity in patients who are treated 
by either TIL cell therapy or checkpoint blockade.(162,163) 
Furthermore, following this early work, the identification 
of neoantigens on the basis of cancer exome data has 
been documented in a variety of experimental model 
systems and human malignancies.(159,164-173) Based on 
data collected over the past few years, it is plausible that 
neoantigen-specific T cell reactivity forms a major active 
Cancer Vaccine Therapy
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concerning the choice of patients and stage of disease.
 The immunosuppressive microenvironment of a tumor 
can inhibit the effect of therapeutic vaccines, both during 
the immunity induction and in the response effector phase. 
So, the negative regulators of the activation of effector T 
cells  need to be blocked to improve the induction phase.
(195) Antibodies against one such molecule, CTLA-4 are 
being evaluated in clinical trials.(196,197) CTLA-4 is 
expressed on activated T cells, where it serves as a brake 
halting the activation. Blocking activity of CTLA-4 allows 
larger expansion of all T-cell populations, presumably 
including those with antitumor reactivity. In a recent pilot 
trial involving 14 patients with hormone-refractory prostate 
cancer, systemic treatment with anti-CTLA-4 antibody 
increased antitumor immunity, resulting in a reduction in 
prostate-specific antigen of more than 50% in two patients 
and less than 50% in eight patients.(197) The side effects 
were rash and pruritus, which required treatment with 
corticosteroids in the two patients with the best response.
(62)
 Approaches to eliminating immunosuppressive 
regulatory T cells before vaccination are also being tested. 
One promising reagent is Denileukin diftitox (Ontak, 
Seragen), a recombinant fusion protein composed of IL-2 
and diphtheria toxin. It targets the high-affinity IL-2 receptor 
(CD25), which is displayed in abundance by regulatory 
T cells. When administered to patients with melanoma, 
protein depletes the blood of regulatory T cells. In most 
patients (90%), this treatment has resulted in the production 
of melanoma-specific CD8 T cells.(198)
that adjuvants act primarily because they are DC activators.
(180) Therapeutic vaccines in chronic infections (or cancer) 
have two objectives: one is priming, whereas the other one 
is the modulation or reprogramming of memory cells, i.e., 
to transition from one type of immunity to another (e.g., 
regulatory to cytotoxic).
 Tumor cells themselves are poor APC, which raises 
the question of how such potent immunity can be generated. 
Mouse models demonstrate that the generation of protective 
anti-tumor immunity relies on the presentation of tumor 
antigens by DC.(181,182) These cells special features in 
coordinating innate and adaptive immune responses provided 
an idea for a DCs-involved vaccination strategies, aiming 
to induce tumor-specific effector T cells that can reduce 
the tumor mass specifically and induce the immunological 
memory to control tumor relapse. First step for these 
processes is to provide DCs with tumor-specific antigens. 
This can be achieved either by culturing ex vivo patients-
derived DCs that have been induced with an adjuvant 
(induces DC maturation) and the tumor-specific antigen, 
and then injecting these cells back into the patient, or by 
inducing DCs to take up the tumor-specific antigen in vivo. 
To improve therapeutic use of DC vaccination strategies, 
it is necessary to understand the biology of DC and how 
they regulate the innate and the adaptive immune systems, 
particularly in the context of the tumor microenvironment.
(183)
 Most phase 1 and phase 2 trials of cancer vaccines have 
involved patients with an extensive cancer burden, impaired 
immune function, or both.(184) An alternative to infusion 
of preformed tumor-specific antibodies or T cells, known as 
passive immunotherapy, is active specific immunotherapy 
(i.e., cancer vaccines) designed to elicit or boost similar 
tumor antibodies and T cells in patients. Some examples 
are vaccines against breast cancer (the HER2 antigen) (185-
7), B-cell lymphoma (the tumor immunoglobulin idiotype) 
(188), lung cancer (the Mucin 1 cell surface associated 
(MUC1) antigen) (189), melanoma (DC loaded with tumor 
peptides or killed tumor cells) (190,191), pancreatic cancer 
(telomerase peptides) (192), and prostate cancer (DC loaded 
with prostatic acid phosphatase) (193). The results of these 
trials are promising because in each there was evidence of 
an immune response to the vaccine, and in a few cases there 
were clinical responses with minimal or no adverse effects. 
Regarding the limited number of completed phase 3 trials, 
most have failed to presentate a significant benefit with 
respect to predetermined end points (194), but nevertheless 
provided information for design of future trials, especially 
We now have detailed knowledge of the molecular basis 
of cancer to allow a more personalized treatment based 
on genomic sequencing of an individual’s cancer cells 
to identify specific mutations in genes. These mutations 
can then be targeted with compounds to blockade the 
downstream pathways which drive cancer development 
and progression. Thus, each specific mutation serves as the 
predictive biomarker for selecting patients for treatment 
with a given agent.
 Clinical data generated principally over the past 
5 years offer that we are at the threshold of golden era 
for adoptive T cell therapy, where advances in basic 
immunology have informed the development of a new field 
of synthetic immunology which may increase the potency 
Conclusion
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